 Enzo Biochem, Inc. ENZ, a leading biosciences and diagnostics company, today announced it has received a patent for the treatment of liver cancer, U.S. Patent No. 10,675,255 entitled Sphingosine Pathway Modulating Compounds for the Treatment of Cancers. Enzos patent is directed to methods for treating hepatocellular carcinoma HCC, the most common human liver cancer, using the companys proprietary compound SK1-I and has a term extending into June 2038. 